Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Q3 2023 Earnings Presentation
11 slides from Tarsus Pharmaceuticals's earnings presentation, Nov 9, 2023
Slide 1: Third Quarter 2023 Financial Results Conference Call
Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call November 9, 2023 © Tarsus Pharmaceuticals
Slide 2: Today's Speakers
Today’s Speakers Bobak Azamian, Aziz Mottiwala Jeff Farrow M.D., Ph.D. Chief Commercial Chief Financial Officer Chief Executive Officer and Chief Strategy Officer and Chairman Officer 2 © Tarsus Pharmaceuticals – For Investor Purposes Only
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe
Slide 4: XDEMVY: The First and Only FDA-Approved Therapeutic for Demodex Blepharitis
XDEMVY®: The First and Only FDA-Approved Therapeutic for Demodex Blepharitis: A Pervasive and Damaging Eyelid Disease ~25 Million Affected1,2 >7 million proactively seeking treatment for complementary eye conditions / diseases 1.5 million already diagnosed and seeking a solution3 ✓ July 24 – FDA-app
Slide 5: XDEMVY: An Eye Care Launch Unlike Any Other
XDEMVY®: An Eye Care Launch Unlike Any Other $1.7 million in Q3 net product sales An innovative and category creating therapeutic… – First and only FDA approved treatment for Demodex blepharitis With a compelling value proposition… – Robust clinical profile and broad reimbursement potential And a co
Slide 6: Real Patient Examples of Demodex Blepharitis
Real Patient Examples of Photo Credit: Marc Bloomenstein, OD Demodex Blepharitis Before XDEMVY Photo Credit: Vin Dang, OD Photo Credit: Neda Shamie, MD 6 | © Tarsus Pharmaceuticals – For Investor Purposes Only Photo Credit: Joshua Davidson, OD Photo Credit: Joshua Davidson, OD
Slide 7: Lucas – Bakersfield, CA – Retired Engineer; Fencer
Lucas – Bakersfield, CA – Retired Engineer; Fencer Before XDEMVY Photo Credit: Vin Dang, OD After 5 weeks on XDEMVY “I’ve definitely felt an improvement. My eyes feel less sticky in the morning. I like knowing XDEMVY is getting to the root of the problem.” 7 © Tarsus Pharmaceuticals – For Investor P
Slide 8: Positioned for Growth
Positioned for Growth Initiated treatment with XDEMVY Seasoned Leadership Impactful Disease High Touch Growing Initial and Field Team Education Patient Access Demand Industry-leading team with ~70% of ECPs surveyed Active contract negotiations >2,0001 ECPs have started decades of biotech, eye care r
Slide 9: Looking to the Future: Category-Creating Pipeline With Near-Term Catalysts
Looking to the Future: Category-Creating Pipeline With Near-Term Catalysts Tarsus Product Portfolio Product Candidate Indication Formulation Preclinical Phase 1 Phase 2 Phase 3 Milestone Demodex blepharitis U.S. FDA Approved XDEMVY® Eye drop (WW) (Launched Aug. 2023) Demodex blepharitis TP-03 Eye dr
Slide 10: Third Quarter 2023 Financial Results
Third Quarter 2023 Financial Results $1.7 million in net 73% gross-to-net discount product sales Better than anticipated Five weeks in the market non-contracted coverage 1,700 XDEMVY bottles $247 million in cash dispensed to patients Strong foundation enables continued Steady week-over-week growth i
Slide 11: Closing Remarks and Q&A
Closing Remarks and Q&A 11 © Tarsus Pharmaceuticals – For Investor Purposes Only
Tarsus Pharmaceuticals — Q3 2023 Earnings Presentation on 6ix